Navigation Links
Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study

INDIANAPOLIS, July 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation of schizophrenia. In study HBBM, pomaglumetad methionil did not separate from placebo in the primary efficacy endpoint in either the overall or predefined genetic subpopulation (based on the Positive and Negative Syndrome Scale, PANSS) at the two doses investigated (40 mg and 80 mg BID). The active control, risperidone, did separate from placebo in both populations. Pomaglumetad methionil was generally well tolerated in this study, with no new safety findings compared to previous trials. Data will be shared at a later date at an appropriate scientific venue.

HBBM was intended to be the first of two clinical trials to support registration of the compound for monotherapy in acute schizophrenia. The second registration clinical trial, H8Y-MC-HBBN (HBBN), is ongoing. The company will conduct an interim analysis of study HBBN which will provide results later in the year. Additionally, Lilly awaits results from the recently concluded study H8Y-MC-HBCO (HBCO). HBCO is a Phase II study exploring pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics. Data from these two studies will help inform decisions on the future development of pomaglumetad methionil. Ongoing clinical trials with pomaglumetad methionil continue.

"Unfortunately negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories. "Despite all of the advances, the need for new and better treatments for those suffering with mental illnesses is among the most urgent in medicine.  Lilly has long been a pioneer in neuroscience, and we're committed to discovering and delivering breakthrough treatments that make a difference for patients.  Right now, we're developing more than a half dozen potential new medicines to treat neuroscience-related diseases and disorders, including among others, depression, Alzheimers disease and schizophrenia."

About Pomaglumetad Methionil

Pomaglumetad Methionil (mGlu2/3) is a glutamatergic-based agent that, unlike all currently available antipsychotic drugs, does not interact with those central nervous system receptors that are thought to be responsible for many of the intolerable adverse events (e.g., motor dysfunction, reproductive hormone irregularity, weight gain, lipid elevation) associated with present schizophrenia treatments.   

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at


This press release contains forward-looking statements about the potential of LY2140023 monohydrate for the treatment of schizophrenia, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the compound will receive regulatory approval, or that it will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: )

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Diabetes Announces Once Upon A Time Contest Winner
2. Lilly Statement on Affordable Care Act Ruling by Supreme Court
3. Lilly Statement on PDUFA Vote by Senate
4. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
5. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
6. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
7. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
10. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
11. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
Post Your Comments:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):